Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

SIB-1508Y associated with improvement in cognitive deficits in Parkinson's model

March 17, 1997

Repeated IVIg for relapsing-remitting MS

March 17, 1997

First approval for Zomig; antimigraine agents in development

March 14, 1997

Substance P antagonists described by Pfizer

March 14, 1997

Knoll claims two series of compounds for CNS disorders

March 14, 1997

Akzo Nobel reveals new dopamine antagonists

March 14, 1997

NMDA antagonists claimed by Novartis

March 14, 1997

Antiparkinson Rx from Sumitomo in pivotal European trials

March 13, 1997

Somatostatin receptor antagonists prepared by Novartis

March 13, 1997

First approval for naratriptan

March 12, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 29, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
Researchers identify innate immune barrier against melanoma
BioWorld
Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers
BioWorld Science
Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...
Medtronic bolsters pain portfolio in $650M SPR Therapeutics buy
BioWorld
Medtronic plc is strengthening its pain management portfolio with its $650 million move to buy SPR Therapeutics Inc. and bring the company’s peripheral nerve...